Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-09-09

Clinical Trial Update: Pathogenesis of Uric Acid Nephrolithiasis: Role of Pioglitazone/Weight Loss [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating the role of pioglitazone and weight loss in the pathogenesis of uric acid nephrolithiasis (completed).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • PIOGLITAZONE (Pioglitazone)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Nephrolithiasis, Uric Acid | Phase 4 | Status: COMPLETED